Fenofibrate is a third-generation fibric acid derivative indicated as a monotherapy to reduce elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, and apolipoprotein B; to increase high-density lipoprotein cholesterol in patients with primary hyperlipidemia or mixed dyslipidemia; and to reduce triglycerides in patients
12 Fenofibrate and fenofibric acid are Food and Drug Administration (FDA)-approved for the treatment of hypercholesterolemia and mixed dyslipidemias, as well as hypertriglyceridemia.
marketed formulations, and is approved for coadministration with a statin
In particular, there was no significant difference between fenofibrate plus simvastatin recipients and placebo plus simvastatin recipients in the incidence of serious
Share Abstract Background Safe, effective, and readily available drug therapies are required for the management of hyperlipidemia and its associated complications in dogs